- Home
- JHI vs BMEA Comparison
JHI vs BMEA Comparison
Compare JHI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- BMEA
- Stock Information
- Founded
- JHI 1971
- BMEA 2017
- Country
- JHI United States
- BMEA United States
- Employees
- JHI N/A
- BMEA N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- BMEA Health Care
- Exchange
- JHI Nasdaq
- BMEA Nasdaq
- Market Cap
- JHI 124.2M
- BMEA 145.0M
- IPO Year
- JHI N/A
- BMEA 2021
- Fundamental
- Price
- JHI $14.13
- BMEA $3.46
- Analyst Decision
- JHI
- BMEA Buy
- Analyst Count
- JHI 0
- BMEA 13
- Target Price
- JHI N/A
- BMEA $27.92
- AVG Volume (30 Days)
- JHI 29.5K
- BMEA 411.1K
- Earning Date
- JHI 01-01-0001
- BMEA 03-31-2025
- Dividend Yield
- JHI 6.80%
- BMEA N/A
- EPS Growth
- JHI N/A
- BMEA N/A
- EPS
- JHI 1.05
- BMEA N/A
- Revenue
- JHI N/A
- BMEA N/A
- Revenue This Year
- JHI N/A
- BMEA N/A
- Revenue Next Year
- JHI N/A
- BMEA N/A
- P/E Ratio
- JHI $12.47
- BMEA N/A
- Revenue Growth
- JHI N/A
- BMEA N/A
- 52 Week Low
- JHI $11.63
- BMEA $3.25
- 52 Week High
- JHI $13.40
- BMEA $19.36
- Technical
- Relative Strength Index (RSI)
- JHI 53.98
- BMEA 34.96
- Support Level
- JHI $14.15
- BMEA $3.25
- Resistance Level
- JHI $14.24
- BMEA $3.75
- Average True Range (ATR)
- JHI 0.08
- BMEA 0.24
- MACD
- JHI 0.00
- BMEA 0.00
- Stochastic Oscillator
- JHI 54.17
- BMEA 21.43
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.